EACS2023: 531 COCOVIH: decrease in healthcare consumption by French PLHIV in 2019 over the last decade, comparison with other European countries F. Prevoteau du Clary , J.M. Livrozet , D. Zucman , C. Majerholc , A. Vallée , S. Bouée , GERVIH - Groupe d'Etude et de Recherche Ville Hôpital University Hospital Center of Toulouse, Sexual Health Center, Toulouse, France, HCL - Edouard Herriot Hospital, Infectious and Tropical Diseases Department, Lyon, France, Foch Hospital, Internal Medicine, Suresne, France, Foch Hospital, Internal Medicine, Suresnes, France, Foch Hospital, Department of Epidemiology - Data - Biostatistics, Suresnes, France, CEMKA-EVAL, Pharmaco-Epidemiology, Bourg la Reine, France General data Abstract category: Access and delivery of care Abstract body Purpose: COCOVIH is a French retrospective observational study carried out between 2006 and 2019 using the French Nationwide Insurance Database (“Système National des Données de Santé” [SNDS]) to explore the profile, co-morbidities and therapeutic management of PLWHIV. We studied consumption and care pathways for people living with HIV in 2019. Method: The cohort of PLHIV 2006-2019 extracted contains N=247,479 patients according to the following criteria: long-term disease allowed for HIV, hospitalisation coded as HIV, delivery of antiretroviral treatment, HIV-specific biological tests. It was matched (1:1) to an HIV-negative control cohort according to age and sex. Analysis covers the case and control populations alive up to 31 december 2019. Results: After excluding people treated with PrEP (N=18,017), newborns of HIV-positive mothers receiving prophylactic treatment and PLWHIV who did not seek care between 2009 and 2016 (N=18,338), the study population was 211,124 PLWHIV.After excluding those lost to follow-up (N=30,330) and deaths over the period 2006-2018 (N=18,872), the number of PLWHIV in 2019 was N=161,922, and a total of N=148,737 PLHIV and their controls could be analysed for healthcare consumption.In 2019, the average cost of care for a person living with HIV is €12,523.60, compared with €2,445.20 for controls, representing an economic burden of €10,078.40. These results are close to those of most European countries.Twice as many hospital admissions. Three quarters of PLHIV consulted a hospital doctor during the year. Adjusted for their profiles and co-morbidities, the use of outpatient professionals is double that of the general population. Conclusions: In 2019, HIV infection increases healthcare costs fivefold. Outpatient accounts for 78.5% of this burden, with antiretrovirals accounting for 80% of pharmacy expenditure. Per capita healthcare expenditure fell by more than 15% between 2010 and 2019. Despite the use of different methods, the same trend can be observed in six European countries. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 1 2 3 4 5 6 23
RkJQdWJsaXNoZXIy Mzc2ODc=